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a b s t r a c t
Benign tremulous parkinsonism (BTP) is characterized by prominent resting tremor com-
bined with action and postural components, and with only subtle rigidity and bradykinesia.
This tremor is frequently disabling and poorly responsive to therapy with levodopa. Thus,
BTP could be considered either as a distinct clinical disorder or a variant of PD. We present a
case of a 57-year-old man who had a 3-year history of severe and functionally disabling
resting tremor with action and postural features bilaterally but with left dominant hand
predominance. There was only very mild rigidity and bradykinesia and no postural insta-
bility. His tremor was refractory to dopaminergic therapy, including carbidopa/levodopa.
The dopamine transporter (DAT) imaging showed reduced tracer uptake in the putamen
bilaterally, more so on the right side. He was treated with deep brain stimulation (DBS)
targeting the right ventral intermediate nucleus of the thalamus. His tremor resolved
immediately after procedure. The DAT imaging abnormalities indicate the presynaptic
dopamine deﬁciency. In some autopsied BTP cases classic alpha-synuclein pathology of
PD was observed. Thus, despite the lack of levodopa responsiveness BTP likely represents a
variant of PD and not a distinct neurodegenerative disorder. DBS should be considered for
patients with BTP PD variant despite their poor responsiveness to levodopa treatment.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Benign tremulous parkinsonism (BTP) is characterized by
severe resting tremor that is usually asymmetric and
predominantly affects the upper extremities [1]. Action tremor* Corresponding author at: Department of Neurology, Mayo Clinic, 450
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well. The tremor is often problematic because it is refractory to
dopaminergic therapy. Other cardinal parkinsonian signs such
as rigidity, bradykinesia, and postural instability are usually
mild. These symptoms either do not progress or progress very
slowly over the time [1]. It is common for patients with BTP to0 San Pablo Road, Jacksonville, FL 32224, United States.
p. z o.o. All rights reserved.
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tremors [1,2]. In some cases BTP can resemble essential tremor
(ET) due to signiﬁcant action and postural features.
Josephs et al. argued that BTP may be a distinct disorder
similar to but distinguishable from PD [1]. Others suggest that
BTP is a variant of classic PD [3,4]. Here we present a case of BTP
with levodopa-refractory resting tremor in which the tremor
was completely resolved after deep brain stimulation (DBS).
2. Case report
A 57-year-old, left-handed American man presented with a
3-year history of hand tremor. He had severe and persistent
resting tremor with postural and kinetic components that
affected mostly his left hand (Video 1). He had only mild
tremor in his right hand when operating a computer mouse.
He was able to cope with basic daily living activities but with
signiﬁcant compromise. Drinking and writing were difﬁcult.
His tremor forced him to proceed with earlier retirement from
his work as travel agent. He also had mild, bilateral upper
extremity rigidity and reduced arm swing, with left side
predominance.
His past medical history was unremarkable; in particular he
denied a history of head trauma, encephalitis, and exposure to
industrial toxins or psychotropic medications. However, his
father, two paternal aunts and his maternal grandfather had
PD. His father had akinetic-rigid type of PD without any tremor.
Additionally, his mother, maternal grandmother, and sister
had ET. None of them were examined by us for the
independent veriﬁcation of their diagnosis. Pedigree is
depicted in Fig. 1A. He did not carry the most common
autosomal dominant PD gene mutation, LRRK2 p.Gly2019Ser.
The results of his brain MRI were normal. Dopamine
transporter (DAT) imaging showed reduced tracer uptake in
the putamen bilaterally, but the right side displayed less
uptake (Fig. 1B). He was treated with various combinations
of trihexyphenidyl, primidone, amantadine, pramipexole,Fig. 1 – Pedigree and dopamine transporter imaging. The
proband's father, two paternal aunts, and the proband's
maternal grandfather had Parkinson's disease. The
proband's mother, maternal grandmother, and sister had
essential tremor. Standard pedigree symbols are used;
arrow, the proband; circles, female; squares, male; slush
through symbols, diseased individuals; ET, essential
tremor; PD, Parkinson's disease (A). Dopamine transporter
imaging shows decreased tracer uptake in the putamen
bilaterally, and this was more prominent on the right side
(B).propranolol, and carbidopa/levodopa (250 mg three times
daily) alone or with entacapone, with very minimal or no
beneﬁt.
We diagnosed him as having BTP since his phenotype
fulﬁlled the characteristic features of BTP description except
for disease duration; the duration of his illness was only 3
years as opposed to classic descriptions that is usually at least
8 years [1]. Although there were no signiﬁcant changes to his
UPDRS part III score between the worst-off and the best-on
(score = 13; documented at his mid-dose state 3 h after the last
dose anti-parkinsonian medication), and there was no differ-
ence in the Total Tremor Rating Score (25; items 15–21 = 12)
with or without anti-parkinsonian medication on two separate
examination days prior to surgery, we offered the patient
surgical treatment with DBS because his tremor continuously
and markedly impeded his daily activities. He was implanted
with DBS targeting the right ventral intermediate nucleus of
the thalamus. After the procedure his left hand tremor had
completed subsided (Video 2). Ten months after DBS, his left-
hand tremor did not reemerge, but he still had a slight tremor
in his right hand, very mild rigidity, and reduced arm swing
predominantly on his left side. There were no adverse events.
To cope with these residual symptoms, the patient continued
to take the pramipexole and amantadine.
3. Discussion
A core feature of BTP is resting hand tremor. Our patient's most
prominent symptom was resting tremor, which was substan-
tially more severe than mild action (postural and kinetic)
tremor. Although an alternative diagnosis of ET could be
considered, the presence of presynaptic neuronal dysfunction
as evidenced by his DAT scan, suggests that the underlying
etiology is parkinsonism rather than ET. One case series found
that 17 out of 26 BTP cases (65%) had reduced striatal tracer
uptake on DAT imaging [3] (Table 1). In our case, other mild
parkinsonian signs such as asymmetric rigidity and bradyki-
nesia further supported the diagnosis of parkinsonism. In
another case series, nearly three quarters (16/21) of the cases
that had a clinical diagnosis of BTP were autopsy-proven PD
[4]. In addition, some BTP cases have had mutations in PD-
associated genes, such as LRRK2 and parkin [3–5]. These
radiologic, pathological, and genetic observations support
the notion that BTP can be a variant of PD. However, BTP cases
without Lewy body pathology have also been reported [4,6],
suggesting that BTP may be a heterogeneous condition.
Our patient's symptoms were unresponsive to levodopa. In
classic PD, tremor is usually very responsive to this therapy. In
general, PD patients with poor or no responsiveness to
levodopa are considered to be poor candidates for DBS surgery
[7]. Nevertheless, we offer our patient a DBS procedure
designed to combat his tremor and had an excellent outcome.
In one case series of 15 BTP cases treated with DBS, all
improved with a long-lasting beneﬁcial effects for the median
of 4 years after the procedure [2]. This beneﬁcial response was
observed for shorter period (one month to three years) in 3 only
cases [1]. However, none of these DBS cases had DAT testing
performed. There has been only one reported case of BTP in
whom DAT imaging showed bilaterally reduced tracer uptake
Table 1 – Summary of previous reports of BTP and our case.a
Reference No. of
cases
Family
historyb
Refractoriness
to levodopa
Cases treated
with DBS
Cases with DAT
imaging
Pathological
analysis
Genetic analysis
No. (%) No. (%) No. Effective:
No. (%)
No. Reduced
striatal uptake:
No. (%)
Case series
1 16 10 (63) 12 (75) 3 3 (100) NA NA NA NA
2 15 6 (40) 15 (100) 15 15 (100) NA NA NA NA
3 26 16 (62) 23 (88) NA NA 26 17 (65) NA LRRK2 mutation
(V2390 M) in one case
4 21 5 (24) 15 (71) NA NA NA NA PD in 16 cases/
No speciﬁc
pathology
in 5 cases
Parkin mutation
in one case
Case reports
5 1 Yes No No – Yes Yes NA LRRK2 mutation
(G2019S)
6 1 Yes Yes No – No – AD (unrelated) NA
8 1 No Yes Yes Yes Yes Yes NA NA
Our case 1 Yes Yes Yes Yes Yes Yes NA No mutation in
LRRK2 (G2019S)
a AD = Alzheimer's disease; DAT = dopamine transporter, DBS = deep brain stimulation, NA = not available; PD = Parkinson's disease.
b Family history includes tremor and/or Parkinson's disease.
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subthalamic nucleus [8]. Similar to our patient, the tremor
in this case resolved after DBS, and a tremor-free state
continued for at least one year [8]. None of the pathologically
studied BTP cases were treated with DBS.
4. Conclusion
We presented the case whose levodopa-refractory tremor
completely resolved after DBS implantation. DBS has a
potential to greatly beneﬁt patients who have disabling
levodopa-refractory resting tremor. However, the long-term
effects of DBS are still unknown. Prospective studies of more
BTP cases are needed to investigate the natural disease course,
its neuropathological basis, and the long-term effects of DBS
on BTP.
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